Introduction
Rheumatoid arthritis (RA) is a chronic inflammation characterized by the infiltration of inflammatory cells in the joint synovium, causing joint destruction, disability, and pathological change of extra-articular sites. Recently, the pathogenesis of RA demonstrated that the aberrant activation of innate and adaptive immune cells by the complex interaction between genetic and environmental factors, which disrupts the immune tolerance, causes the presentation of autoantigen and inflammatory cytokine secretion [
1,
2]. Various immune cells have been found in the joint of patients with RA, especially CD4
+ T cells, B cells, and macrophages [
3,
4]. Cytokines produced by macrophage activate fibroblast-like synoviocytes and osteoclasts, promote bone destruction, and drive CD4
+ T cell polarization and B cell activation [
3,
5]. Th1 cells are originally thought to be one of the main pathogenic factors of RA. Recently, IL-17 and Th17 cells have been thought to have critical roles in RA pathogenesis. CD14
+ monocytes from the inflamed joints of patients with RA can potently induce Th17 cells instead of Th1 cells [
6]. Furthermore, B cells/plasma cells produce autoantibodies especially rheumatoid factors (RF) and anti-citrullinated peptide antibodies (ACPAs), which promote T cell activation [
7,
8]. Thus, autoreactive T and B cells play a critical role in the pathogenesis of RA.
In addition to B and T cells, innate lymphoid cells (ILCs) are considered to play an important role in the pathogenesis of RA. Helper-like lymphoid cells, as the most prominent ILCs, are usually classified into ILC1, ILC2, and ILC3 subsets and are counterpart of Th cells [
9]. Similar to Th cells, ILC1s require T-bet and produce IFN-γ. ILC2s express GATA3 and secrete IL-4, IL-5, and IL-13. ILC3s express RORγt and secrete IL-17 and IL-22. ILCs can be a bridge between innate and adaptive immunity, thereby mediating inflammatory responses, including RA [
9]. Takaki-Kuwahara and colleagues reported that CCR6
+ILC3s increases in joints of arthritic mice and patients with RA, and CCR6
+ILC3s may participate in the development of RA by producing IL-17 and IL-22 [
10]. However, Yang and colleagues found that stable patients with RA have increased proportions of ILC2s and reduced percentages of ILC1s and ILC3s. The percentages of ILC1s and ILC2s are increased in mice with collagen-induced arthritis (CIA), indicating that the dysregulation of ILCs participates in the development of RA and CIA [
11]. Thus, we hypothesized that intrinsic and acquired immune cell imbalances, accompanied with the production of inflammatory cytokines, are associated with the development of RA. An improved understanding of the role and function of the abovementioned innate and adaptive immune cells, especially ILC subsets, in the pathogenesis of RA can provide new interventions for the treatment of RA.
In this study, we analyze the immune cells especially ILCs and their three subsets in the peripheral blood of patients with RA by flow cytometry. We demonstrate that the proportions of CD4+T, CD19+B, Th17, ILC2, and ILC3 cells in the peripheral blood of patients with RA increase, and the proportions of Treg and ILC1 cells decrease. The percentages of CD19+ B, Th17, ILC2s, and ILC3s increase in RF- (RF+) or ACPA-positive (ACPA+) patients. The percentages of ILC1s and Treg cells decrease in RF+ or ACPA+ patients. The above immune cells have not been found with a significant difference between RF or ACPA seropositive and seronegative patients, suggesting that the dysregulation of these immune cells may not be associated with conventionally defined seropositive RF and ACPA.
Discussion
RA is a chronic inflammatory disease. Although the pathogenic mechanisms of RA have not been fully elucidated, the aberrant activation of innate and adaptive immune system with consequent production of autoantibodies and inflammatory cytokines participates in the development of RA [
18]. In this setting, various immune cells, such as T cells, B cells, and other innate immune cells, form a complex network and produce proinflammatory cytokines, which eventually lead to joint damage [
3]. In addition to adaptive T and B cells, the ILCs involved in inflammatory and autoimmune responses have been confirmed to participate in the pathogenesis of RA [
3]. Rauber and colleagues demonstrated that patients with RA and in remission have high numbers of IL-9
+ILC2s [
24]. In the present study, we demonstrated that patients with RA have upregulated percentages of circulating CD4
+ T, CD19
+ B, Th17, ILC2s, and ILC3s and downregulated percentages of Treg and ILC1s. Increased Th17 and decreased Treg frequencies in patients with RA in the present study are consistent with previous studies [
19,
20]. In contrast to the reduction of ILC1s and increase of ILC3s in PBMC of patients with RA, Leijten and colleagues reported that the frequencies of ILC1s increase, and ILC3s decrease in the synovial fluid (SF) of patients with RA [
25]. ILCs initially serve as tissue “sentinel,” which can produce a variety of cytokines upon activation in an inflammatory environment. Furthermore, ILCs initiate helper T cell responses [
26], and activated Th cells produce proinflammatory cytokines in chronic inflammation. Consistent with increased ILC2s and ILC3s frequencies, IL-4 and IL-17 levels in the sera of patients with RA are also increased. However, whether IL-4 is secreted from ILC2s or Th2 and whether IL-17 is produced from ILC3s or Th17 are unclear. Inconsistent with the decrease in ILC1s percentage, the IFN-γ level in the sera of patients with RA is increased. Th1 cells and IFN-γ have been suggested to contribute to the pathogenesis in RA[
27], and IL-4 and other Th2 cytokines downregulate the inflammatory processes in RA [
28,
29]. However, SF from patients with early arthritis display increased Th2 cytokines, such as IL-4 and IL-13, but not Th1-related IFN-γ [
30]. Furthermore, Kokkonen and colleagues reported that the sera from patients after the development of RA show increases in Th1-related IFN-γ, Th2-related IL-4 and IL-13, and immune regulation IL-10 [
31]. In addition, IFN-γ may be derived from Th17 and CD8
+ T cells (Tc1 cells) in patients with RA [
27,
32] although we have not identified IFN-γ-producing cells. Consistent with the increase in Th17 cells, the levels of IL-22, a Th17-related-effector molecule, in the sera of patients with RA increase [
32]. However, the IL-10 level in the sera of patients with RA in this study is decreased, which is contrary to other studies in which IL-10 is elevated in blood and SF [
31,
33]. The IL-10 level in this study is consistent with another study, demonstrating that the IL-10 concentration in culture supernatants from PBMCs and SFMCs in patients with RA is lower than that in healthy controls [
34]. The differences in immune cells and cytokines from patients with RA may be related to the difference in disease populations and stages. The dysregulation of these immune cells and cytokines may reflect inflammation rather than specific diseases.
Consistent with the view that Th17 and IL-17 have dominant pathogenic roles in RA [
32], the Th17 cell frequency is increased in patients with high disease activity, whereas the Treg percentage is decreased. These results are consistent with the findings that active patients with RA have high expression of RORc mRNA and low expression of FoxP3 mRNA than that of inactive patients and healthy controls [
35], because FoxP3 and RORc are the lineage-specific transcription factors of Treg and Th17 cells. In contrast to stable patients who have increased ILC1s and decreased ILC2s [
11], patients with high disease activity have decreased ILC1s and increased ILC2s and ILC3s. Although ILC2s is thought to be involved in the resolution of inflammation in RA [
24,
36], GM-CSF-producing ILC2s is reported to play a pathogenic role in the development of arthritis [
37]. Takaki-Kuwahara A et al. revealed that the proportion of ILC1s in SF is negatively correlated with tender (TJC) and swollen (SJC) joint counts, but NKp44
+ILC3s is positively correlated with TJC and SJC, suggesting that ILC3s aggravate the inflammation in patients with RA [
10]. Activated ILCs are also important sources of inflammatory cytokines. High frequencies of Th17 and ILC3s are consistent with high levels of IL-17 in patients with RA and high disease activity. Furthermore, a low level of IL-10 is consistent with low frequencies of Treg cells in patients with RA and high disease activity. IL-10 is produced by Treg, Th1, Th2, and other cells [
34]. This finding supports the notion that active patients may exhaust IL-10 due to continuous against inflammation [
38]. Furthermore, these results are consistent with a previous study demonstrating that as inflammation increases, patients reveal low percentage of CD4
+CD25
+ Treg cells [
38]. Thus, the imbalance in the Th17/Treg and ILC subsets involving the production of pro-/anti-inflammatory cytokines is associated with the development and/or progression of RA.
Patients positive for RF and/or ACPA are usually considered to be seropositive and considered to be correlated with high disease activity and poor clinical outcome [
39]. RF
+ and ACPA
+ patients have increased percentages of ILC2s and ILC3s and decreased percentage of Treg and ILC1s relative to healthy controls. The above ILC subsets are not significantly different between RF
+ and RF
− or ACPA
+ and ACPA
− patients. Compared with HC, RF
+, RF
−, ACPA
+, and ACPA
− patients have increased Th17 cells and IL-17A levels. Compared with HC, RF
+ or ACPA
+ patients have decreased Treg cells. However, the frequencies of Th17 and Treg cells show no statistical difference between RF
+ and RF
− patients or between ACPA
+ and ACPA
− patients. Although ACPA has been reported to stimulate macrophages to produce cytokines through the formation of immune complexes and participate in the pathogenesis of RA [
40], we do not observe differences in the above immune cells and cytokines between ACPA
+ and ACPA
− patients. No difference for the distribution of Th17 and Treg cells is observed between ACPA
+ and ACPA
− patients, and this finding is consistent with a previous study [
41]. However, Paulissen et al. reported that ACPA
+ patients show high percentages of Th22, Th17.1, and CCR4/CXCR3 double-positive cells, which are gated from CCR6
+ population and suggested that CCR6 + Th cell differentiates ACPA
+ patients from ACPA
− patients [
41]. Identifying the relationship between immune cell populations and autoantibodies may require identification markers. However, ACPA
+ and RF
+ as “seropositive” are commonly determined by anti-CCP2 IgG and IgM RF, respectively. The CCP2 test does not capture all ACPA because many proteins, such as citrullinated fibrinogen, collagen type II, tenascin C, α-enolase, vimentin, and histones, are recently described as ACPA targets [
42]. Rönnelid and colleagues demonstrated that 16% of anti-CCP2-negative are ACPA
+ in patients with RA by using a multiplex citrullinated peptide array [
43]. Furthermore, the IgA isotype of RF and anti-CCP antibody has been found to be superior to IgM- or IgG-RF and anti-CCP response in mucosal inflammation and is closely associated with the development of RA [
44‐
46]. Thus, Reed E et al. reported that ACPA
− or RF
− is not truly a seronegative subset in patients with RA [
42]. ACPA fine specificities and IgA/IgG RF for anti-CCP2-/IgM RF − patients should be screened, which may contribute to early diagnosis and therapy for these “seronegative” patients [
42]. Thus, immune cell and cytokine dysregulation should be analyzed on the basis of a broad spectrum of RF and ACPA serology. However, this study had limitations because the results were from a limited number of patients, so the sample size needs to be expanded for validation.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.